182 related articles for article (PubMed ID: 22581584)
1. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
Yang CL; Jiang FQ; Xu F; Jiang GX
Tumour Biol; 2012 Oct; 33(5):1535-41. PubMed ID: 22581584
[TBL] [Abstract][Full Text] [Related]
2. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
Huo X; Zhang Q; Liu AM; Tang C; Gong Y; Bian J; Luk JM; Xu Z; Chen J
Oncol Rep; 2013 Feb; 29(2):840-6. PubMed ID: 23232767
[TBL] [Abstract][Full Text] [Related]
4. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
5. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
6. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
7. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
Xu Y; Lai Y; Cao L; Li Y; Chen G; Chen L; Weng H; Chen T; Wang L; Ye Y
RNA Biol; 2021 Oct; 18(10):1408-1423. PubMed ID: 33206588
[TBL] [Abstract][Full Text] [Related]
8. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
Liu WH; Chang LS
Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
10. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
Tian T; Fu X; Lu J; Ruan Z; Nan K; Yao Y; Yang Y
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22167. PubMed ID: 29968951
[TBL] [Abstract][Full Text] [Related]
13. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
14. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
[TBL] [Abstract][Full Text] [Related]
15. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
16. Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells.
Fan L; Song B; Sun G; Ma T; Zhong F; Wei W
PLoS One; 2013; 8(5):e62627. PubMed ID: 23658755
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.
Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.
Yue Y; Shao Y; Luo Q; Shi L; Wang Z
Biomed Res Int; 2013; 2013():434561. PubMed ID: 23936798
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
Wang L; Wang YM; Xu S; Wang WG; Chen Y; Mao JY; Tian BL
Mol Med Rep; 2015 Oct; 12(4):5274-80. PubMed ID: 26135967
[TBL] [Abstract][Full Text] [Related]
20. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
